EUVIMEDEUVIMED entdecken
Open Access

Gene therapy for inborn errors of immunity: past progress, current status and future directions

Robert Torrance, Kate Orf, Thomas A Fox iD

Rare Disease and Orphan Drugs Journal · 14.10.2025 · 4 (4)

DOI: 10.20517/rdodj.2025.42 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rare Disease and Orphan Drugs Journal, online erschienen am 14.10.2025. Verfasst von Robert Torrance und 2 weiteren Autor:innen. Beteiligte Einrichtung: UCL Institute of Immunity and Transplantation, UCL, London NW3 2PP, United Kingdom. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inborn errors of immunity (IEIs), also known as primary immunodeficiencies, are a group of rare inherited disorders that affect the immune system. They result in severe, opportunistic infections, severe autoimmune manifestations and a predisposition to malignancy. The only curative treatment for many years has been allogenic haematopoietic stem cell transplantation (alloHSCT). However, this requires the availability of a suitable donor and has risks of morbidity and mortality. Autologous gene therapy (GT) abrogates the immunological complications of alloHSCT and uses the patient’s own cells, removing the need for a donor. Preclinical proof-of-concept and clinical trials in humans have demonstrated that GT is safe and effective and can be used to correct a variety of IEIs. In this review, we outline the progress in developing GT for IEIs over the last four decades. We describe the gene editing technologies available to correct IEIs and their current applications. We also examine advances in GT development, the challenges to its application, and discuss future developments in the field, including emerging in vivo approaches.

Schlagwörter

Stichwörter der Autor:innen

Gene therapyinborn errors of immunityprimary immunodeficiency

Autor:innen und Institutionen

  • UCL Institute of Immunity and Transplantation, UCL, London NW3 2PP, United Kingdom.
  • Department of Haematology, University College London Hospitals NHS Foundation Trust, London NW1 2PG, United Kingdom.

ORCID-Profile: Thomas A Fox

Förderung

  • Wellcome Trust
  • Medical Research Council

Zitieren

APA

Torrance, R., Orf, K., & Fox, T. A. (2025). Gene therapy for inborn errors of immunity: past progress, current status and future directions. Rare Disease and Orphan Drugs Journal, 4(4). https://doi.org/10.20517/rdodj.2025.42

Vancouver

Torrance R, Orf K, Fox TA. Gene therapy for inborn errors of immunity: past progress, current status and future directions. Rare Disease and Orphan Drugs Journal. 2025;4(4). doi:10.20517/rdodj.2025.42

BibTeX
@article{Torrance2025,
  author = {Torrance, Robert and Orf, Kate and Fox, Thomas A},
  title = {Gene therapy for inborn errors of immunity: past progress, current status and future directions},
  journal = {Rare Disease and Orphan Drugs Journal},
  year = {2025},
  volume = {4},
  number = {4},
  doi = {10.20517/rdodj.2025.42}
}
Kostenlos starten →